MENU
SPRC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SPRC stock forecast, quote, news & analysis

SciSparc Ltd is a specialty clinical stage pharmaceutical company... Show more

SPRC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRC with price predictions
Jul 10, 2026

SPRC's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for SPRC moved out of oversold territory on July 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In of the 45 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where SPRC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRC as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SPRC turned negative on June 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

SPRC moved below its 50-day moving average on June 24, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SPRC crossed bearishly below the 50-day moving average on June 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SPRC entered a downward trend on July 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.618) is normal, around the industry mean (22.885). P/E Ratio (0.047) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). SPRC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.663) is also within normal values, averaging (434.181).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SPRC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 58 to 121.89B. VRTX holds the highest valuation in this group at 121.89B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 1,806%. FBRX experienced the highest price growth at 116%, while ENLV experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 52
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
SPRC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
20 Raul Wallenberg Street
Phone
+972 37175777
Employees
2
Web
https://www.scisparc.com
SPRC's RSI Oscillator climbs out of oversold territory